Antisense & RNAi Therapeutics Global Market Report 2024

The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period of antisense and RNAi therapeutics can be attributed to increased funding, advancements in technologies, rising healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets.

The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The anticipated growth in antisense and RNAi therapeutics is driven by factors such as improved healthcare access, a growing cancer prevalence, and increased demand due to COVID-19. Key trends include research and development focus on RNA therapeutics for orphan diseases, utilization of nanoparticles, innovation in antisense and RNAi therapeutics, and collaboration for product innovation to boost revenues.

The escalating incidence of coronary artery diseases, neurodegenerative disorders, and infectious ailments is anticipated to fuel the demand for the antisense & RNAi therapeutics market. These gene suppression methodologies, such as RNA interference and antisense oligonucleotides, are utilized in treating various neurodegenerative ailments by rectifying defective genes. Notably, Alzheimer's disease and Parkinson's disease are among the most widespread neurodegenerative conditions affecting a substantial global population. The USA alone records approximately 6.2 million cases of Alzheimer's disease and about 500,000 diagnoses of Parkinson's disease as of January 2023. Consequently, the increasing prevalence of these neurodegenerative disorders and infectious illnesses is expected to propel the growth of the antisense & RNAi therapeutics market.

The surge in chronic diseases' prevalence is foreseen to drive the demand for antisense & RNAi therapeutics. Chronic diseases encompass long-term health conditions such as cardiovascular ailments, oncological disorders, among others, which lack definitive cures. Antisense and RNA interference (RNAi) therapeutics exhibit promise in treating various cardiovascular diseases by specifically targeting genes or molecular pathways associated with their pathogenesis. As outlined in the World Heart Report 2023 by the World Health Organization (WHO), approximately 20.5 million individuals succumbed to cardiovascular conditions in 2021, constituting nearly one-third of global deaths for that year. Hence, the growing prevalence of chronic diseases is expected to propel the expansion of the antisense & RNAi therapeutics market.

Major companies in the antisense & RNAi therapeutics sector are employing strategic collaborations and partnerships as key initiatives to maintain their positions in an increasingly competitive market landscape. These partnerships involve joint efforts between two or more companies aiming to achieve shared objectives. For instance, in January 2023, Orbit Discovery Limited, a US-based company specializing in peptide discovery services, teamed up with SanegeneBio Inc., a UK-based firm focused on developing innovative RNAi-based medicines. This collaboration aims to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown. The partnership involves hit identification and cell-based internalization studies, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Sanegene gains the opportunity to further develop potential hits derived from the screening activities for advanced RNAi therapeutics.

Major players in the antisense & RNAi therapeutics market are fostering partnerships to forge new relationships aimed at jointly creating innovative products. These strategic collaborations represent cooperative alliances between organizations, pooling their strengths or resources toward common goals. For example, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical giant, and Wave Life Sciences, a US-based company specializing in genetic medicines, announced a collaboration to develop oligonucleotide therapeutics targeting novel genetic markers. By integrating GSK's genetic expertise with Wave's PRISM platform, the collaboration aims to advance up to eight preclinical programs. Additionally, GSK secures an exclusive global license for Wave's WVE-006, a potential RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, leveraging innovative chemistry to optimize the properties of therapeutic oligonucleotides.

In December 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, revealed a strategic partnership with Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company specializing in the discovery and development of RNA-based therapeutics and drugs. As part of this collaboration, the two companies will jointly develop and commercialize Eplontersen in the United States, while AstraZeneca will handle development and commercialization in all other regions outside of Latin America.

Major companies operating in the antisense & rnai therapeutics market report are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd., Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline PLC, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc., Calando Pharmaceuticals, Enzon Pharmaceuticals Inc., Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical.

North America was the largest region in the antisense & RNAi therapeutics market in 2023. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antisense & rnai therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary technologies in antisense and RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA, which plays a role in resisting both endogenous parasitic and exogenous pathogenic nucleic acids, and it regulates the expression of protein-coding genes. Various routes of administration for these therapies include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other methods. These therapies are used for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and others.

The antisense & RNAi therapeutics market research report is one of a series of new reports that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.